JP2011515391A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515391A5
JP2011515391A5 JP2011500740A JP2011500740A JP2011515391A5 JP 2011515391 A5 JP2011515391 A5 JP 2011515391A5 JP 2011500740 A JP2011500740 A JP 2011500740A JP 2011500740 A JP2011500740 A JP 2011500740A JP 2011515391 A5 JP2011515391 A5 JP 2011515391A5
Authority
JP
Japan
Prior art keywords
oxidase
hydrogen peroxide
producing enzyme
medicament
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011500740A
Other languages
English (en)
Japanese (ja)
Other versions
JP5558458B2 (ja
JP2011515391A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2009/050291 external-priority patent/WO2009116944A1/en
Publication of JP2011515391A publication Critical patent/JP2011515391A/ja
Publication of JP2011515391A5 publication Critical patent/JP2011515391A5/ja
Application granted granted Critical
Publication of JP5558458B2 publication Critical patent/JP5558458B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011500740A 2008-03-20 2009-03-20 普通感冒の治療用の医薬の製造における物質の使用 Expired - Fee Related JP5558458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0800658 2008-03-20
SE0800658-7 2008-03-20
PCT/SE2009/050291 WO2009116944A1 (en) 2008-03-20 2009-03-20 Use of a substance for manufacturing of a medicament for treatment of common cold

Publications (3)

Publication Number Publication Date
JP2011515391A JP2011515391A (ja) 2011-05-19
JP2011515391A5 true JP2011515391A5 (enExample) 2012-04-05
JP5558458B2 JP5558458B2 (ja) 2014-07-23

Family

ID=41091160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011500740A Expired - Fee Related JP5558458B2 (ja) 2008-03-20 2009-03-20 普通感冒の治療用の医薬の製造における物質の使用

Country Status (8)

Country Link
US (1) US8895282B2 (enExample)
EP (1) EP2276505B1 (enExample)
JP (1) JP5558458B2 (enExample)
CN (1) CN101977625A (enExample)
DK (1) DK2276505T3 (enExample)
ES (1) ES2436037T3 (enExample)
PL (1) PL2276505T3 (enExample)
WO (1) WO2009116944A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3245871A1 (en) 2014-04-30 2017-11-22 Matoke Holdings Limited Antimicrobial compositions
US10213491B2 (en) * 2015-05-19 2019-02-26 The Penn State Research Foundation Glucose oxidase compositions as a neonate anticonvulsant
US20180280483A1 (en) * 2015-08-21 2018-10-04 Morinaga Milk Industry Co., Ltd. Agent for protecting upper respiratory tract and food or drink composition for protecting upper respiratory tract
CA3038590A1 (en) * 2016-10-06 2018-04-12 Matoke Holdings Limited Antimicrobial compositions
GB201716986D0 (en) 2017-10-16 2017-11-29 Matoke Holdings Ltd Antimicrobial compositions
CN112105378B (zh) 2018-01-03 2025-03-11 宾夕法尼亚州研究基金会 作为新生儿抗惊厥药的葡萄糖氧化酶组合物
CN112351766A (zh) 2018-06-25 2021-02-09 璀昂芬制药公司 使用含锌的组合物抑制微生物感染的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8702831L (sv) 1987-07-10 1989-01-11 Ewos Ab Microbicid komposition
GB9002422D0 (en) 1990-02-03 1990-04-04 Boots Co Plc Anti-microbial compositions
WO1992014484A1 (en) 1991-02-21 1992-09-03 Exoxemis, Inc. Methods and compositions for the treatment of infection and control of flora
US5389369A (en) 1991-02-21 1995-02-14 Exoxemis, Inc. Halo peroxidase containing compositions for killing yeast and sporular microorganisms
GB2285218A (en) * 1993-12-17 1995-07-05 William Elwyn Roberts An aid to recovery from disease caused by bacteria fungi viruses and malignant cells
GB9406075D0 (en) 1994-03-26 1994-05-18 Boots Co Plc Method of killing microorganisms
SE506529C2 (sv) 1996-01-23 1997-12-22 Semper Ab Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
CO4910145A1 (es) 1996-10-01 2000-04-24 Smithkline Beecham Corp Uso
WO1999002148A1 (en) * 1997-07-11 1999-01-21 The Johns Hopkins University School Of Medicine Nitric oxide inhibits rhinovirus infection
DE29723959U1 (de) 1997-07-22 1999-07-22 Zellner, Gerhard, Dr., 83435 Bad Reichenhall Nasenspray-Flüssigkeit
AU7584500A (en) 1999-09-17 2001-04-17 Smithkline Beecham Corporation Use of csaids in rhinovirus infection
US20040033260A1 (en) * 1999-10-19 2004-02-19 The Procter & Gamble Company Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
US6214339B1 (en) 2000-01-12 2001-04-10 Michael A. Pellico Di-enzymatic treatment of outer ear infection in dogs and cats
AR030753A1 (es) 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
SE0200876L (sv) 2002-03-22 2003-09-23 Krister Tano Nässpray mot öroninflammationer
CN1408358A (zh) * 2002-09-20 2003-04-09 高艺歌 一种葡萄糖酸锌(胶体)喷鼻剂的处方组成
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
WO2005113026A2 (en) 2004-04-22 2005-12-01 Medical Discoveries, Inc. Method of treating respiratory disorders and airway inflammation
US20070026085A1 (en) 2005-07-26 2007-02-01 Global Life Technologies Corp. Antimicrobial and antiviral composition
BRPI0617481A2 (pt) 2005-10-21 2011-07-26 Danisco composiÇço que compreende um sistema enzimÁtico acoplado

Similar Documents

Publication Publication Date Title
JP2011515391A5 (enExample)
NL300874I2 (nl) Elosulfase alfa
JP2012530141A5 (enExample)
MX2011008416A (es) Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
NZ593823A (en) Compositions and methods for the treatment or the prevention of infections by e. coli
NZ599298A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011017484A3 (en) Sublingual and buccal film compositions
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
JP2010535786A5 (enExample)
NZ587060A (en) Rna interference for the treatment of heart failure
JP2015514778A5 (enExample)
JP2014501492A5 (enExample)
GB2476202A (en) Novel choline cocrystal of epalrestat
JP2012517449A5 (enExample)
Schreml et al. A new star on the H2O2rizon of wound healing?
MX2007006284A (es) Acidos biariloximetilarenocarboxilicos.
JP2013540803A5 (enExample)
WO2008111956A3 (en) Fatty acid oxidation inhibitors treating hyperglycemia and related disorders
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
MX357507B (es) Metodos para tratar hiperucemia en pacientes con gota utilizando halofenato o acido halofenico y un segundo agente de reduccion de urato.
JP2012525422A5 (enExample)
NZ588927A (en) Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
WO2011061554A3 (en) Pharmaceutical composition for the treatment of bladder disorders
CN201969076U (zh) 带壳聚糖的改性聚乳酸抗粘连生物膜
CN201727562U (zh) 纳米针刀